Active Ingredient History
Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Organ Transplantation (approved 2011)
Abdominal Wall (Phase 2)
Allografts (Phase 3)
Arthritis, Rheumatoid (Phase 2)
Delayed Graft Function (Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2)
Fistula (Phase 2)
Graft Rejection (Phase 4)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 2)
Heart Transplantation (Phase 2)
Hernia, Abdominal (Phase 2)
Herpesvirus 4, Human (Phase 4)
Immunosuppression Therapy (Phase 2)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Liver Transplantation (Phase 2)
Lung Transplantation (Phase 2)
Organ Transplantation (Phase 2)
Proteinuria (Phase 2)
Renal Insufficiency (Phase 1)
Renal Insufficiency, Chronic (Phase 1/Phase 2)
Risk Factors (Phase 2)
Transplantation (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
